211 related articles for article (PubMed ID: 7644349)
21. Density gradient separation of hematopoietic stem cells in autologous bone marrow transplantation.
Iacone A; Quaglietta AM; D'Antonio D; Accorsi P; Dragani A; Angrilli F; Berardi A; Angelini A; Di Bartolomeo P; Di Bartolomeo G
Haematologica; 1991 Mar; 76 Suppl 1():18-21. PubMed ID: 1677910
[TBL] [Abstract][Full Text] [Related]
22. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.
Carlo-Stella C; Tabilio A; Regazzi E; Garau D; La Tagliata R; Trasarti S; Andrizzi C; Vignetti M; Meloni G
Bone Marrow Transplant; 1997 Sep; 20(6):465-71. PubMed ID: 9313879
[TBL] [Abstract][Full Text] [Related]
23. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
Makrynikola V; Kabral A; Bradstock KF
Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
Jiang R; Bony V; Lopez M
Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
[No Abstract] [Full Text] [Related]
25. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.
Novitzky N; Mohamed R
Exp Hematol; 1995 Dec; 23(14):1661-6. PubMed ID: 8542962
[TBL] [Abstract][Full Text] [Related]
26. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
27. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213).
Deconinck E; Tamayo E; Hervé P
Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
[TBL] [Abstract][Full Text] [Related]
29. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
Papadakis V; Ferguson KF; Heller G; Kernan NA
Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
[TBL] [Abstract][Full Text] [Related]
30. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
Kramer B; Makrynikola V; Bradstock K
Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
[No Abstract] [Full Text] [Related]
31. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
[TBL] [Abstract][Full Text] [Related]
32. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
[TBL] [Abstract][Full Text] [Related]
33. Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells.
Nieborowska-Skórska M; Skórski T; Ratajczak MZ; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1993; 31(4):161-7. PubMed ID: 8137996
[TBL] [Abstract][Full Text] [Related]
34. [A simple method for detecting immature precursors after in vitro bone marrow treatment with ASTA-Z 7654].
Lamana M; Fernández-Rañada JM
Sangre (Barc); 1991 Dec; 36(6):501-3. PubMed ID: 1812583
[TBL] [Abstract][Full Text] [Related]
35. The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654).
Genevay MC; Mormont C; Thomas F; Berthier R
Exp Hematol; 1996 Jan; 24(1):77-81. PubMed ID: 8536796
[TBL] [Abstract][Full Text] [Related]
36. The cytotoxicity of mafosfamide on G-CSF mobilized hematopoietic progenitors is reduced by SH groups of albumin--implications for further purging strategies.
Schlenke P; Kisro J; Deeken M; Zajac S; Klich S; Wagner T
Bone Marrow Transplant; 1999 Jan; 23(2):157-61. PubMed ID: 10197801
[TBL] [Abstract][Full Text] [Related]
37. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
Ciobanu N; Paietta E; Andreeff M; Papenhausen P; Wiernik PH
Exp Hematol; 1986 Aug; 14(7):626-35. PubMed ID: 3525202
[TBL] [Abstract][Full Text] [Related]
38. [Purging of hemopoietic progenitor cells in autologous transplantation].
Hrubá A; Skala JP; Matĕjcková S; Fales I; Vodvárková S; Starý J; Kavan P; Kobylka P
Cas Lek Cesk; 1997 Mar; 136(5):151-3. PubMed ID: 9221189
[TBL] [Abstract][Full Text] [Related]
39. Activated lymphocytes in the marrow cell suspension decrease the mafosfamide-induced CFU-GM cytotoxicity.
Woźny T; Sawiński K; Kozłowska-Skrzypczak M; Hansz J
Acta Haematol Pol; 1995; 26(4):367-75. PubMed ID: 8571738
[TBL] [Abstract][Full Text] [Related]
40. Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow.
Rizzoli V; Mangoni L; Almici C; Caramatti C; Dotti GP; Carlo-Stella C
Stem Cells; 1993 Oct; 11 Suppl 3():25-30. PubMed ID: 8298474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
